RFX-1-dependent activation of SHP-1 inhibits STAT3 signaling in hepatocellular carcinoma cells Jung-Chen Su1, Heng-Chieh Chiang2, Ping-Hui Tseng3, Wei-Tien Tai4,5, Cheng-Yi Hsu1, Yong-Shi Li4,5, Jui- Wen Huang6, Ching-Huai Ko6, Mai-Wei Lin6, Pei-Yi Chu7, Chun-Yu Liu1,8,9, Kuen-Feng Chen4,5,* and Chung-Wai Shiau1
نویسندگان
چکیده
1Institute of Biopharmaceutical Sciences, National Yang-Ming University, Taipei 112, Taiwan, 2Transplant Medicine & Surgery Research Centre, Department of Surgery, Changhua Christian Hospital, Changhua City, Changhua County 500, Taiwan, 3Institute of Biochemistry and Molecular Biology, National Yang-Ming University, Taipei 112, Taiwan, 4Department of Medical Research and 5National Center of Excellence for Clinical Trial and Research, National Taiwan University Hospital, Taipei 100, Taiwan, 6Biomedical Technology and Device Research Labs, Industrial Technology Research Institute, Hsinchu 310, Taiwan, 7Department of Pathology, St Martin De Porres Hospital, Chiayi 600, Taiwan, 8Division of Hematology and Oncology, Department of Medicine, Taipei Veterans General Hospital, Taipei 112, Taiwan and 9National Yang-Ming University School of Medicine, Taipei 112, Taiwan
منابع مشابه
RFX1–dependent activation of SHP-1 induces autophagy by a novel obatoclax derivative in hepatocellular carcinoma cells
Obatoclax is a small molecule which targets the Bcl-2 family, and is to treat leukemia, lymphoma and lung carcinoma. Previously, an obatoclax analogue, SC-2001, was found to disrupt the protein-protein interactions of the Bcl-2 family and also repress Bcl-XL and Mcl-1 expression via STAT3 inactivation. Here, we report a novel mechanism of autophagy induction by SC-2001 in liver cancer cells. Th...
متن کاملSC-2001 Overcomes STAT3-mediated Sorafenib Resistance through RFX-1/SHP-1 Activation in Hepatocellular Carcinoma☆☆☆
Hepatocellular carcinoma is the fifth most common solid cancer worldwide. Sorafenib, a small multikinase inhibitor, is the only approved therapy for advanced HCC. The clinical benefit of sorafenib is offset by the acquisition of sorafenib resistance. Understanding of the molecular mechanism of STAT3 overexpression in sorafenib resistance is critical if the clinical benefits of this drug are to ...
متن کاملSTAT3 mediates regorafenib-induced apoptosis in hepatocellular carcinoma.
PURPOSE Here, we aim to investigate the molecular mechanism of regorafenib and verify the potential druggable target for the treatment of hepatocellular carcinoma (HCC). EXPERIMENTAL DESIGN HCC cell lines (PLC5, HepG2, Hep3B, SK-Hep1, and HA59T) were used to investigate the in vitro effect of regorafenib. Phosphatase activity was analyzed in HCC cells and purified SHP-1 proteins. PLC5-bearing...
متن کاملCancer Therapy: Preclinical STAT3 Mediates Regorafenib-Induced Apoptosis in Hepatocellular Carcinoma
Purpose: Here, we aim to investigate the molecular mechanism of regorafenib and verify the potential druggable target for the treatment of hepatocellular carcinoma (HCC). Experimental Design: HCC cell lines (PLC5, HepG2, Hep3B, SK-Hep1, and HA59T) were used to investigate the in vitro effect of regorafenib. Phosphatase activity was analyzed in HCC cells and purified SHP-1 proteins. PLC5-bearing...
متن کاملDisrupting VEGF-A paracrine and autocrine loops by targeting SHP-1 suppresses triple negative breast cancer metastasis
Patients with triple-negative breast cancer (TNBC) had an increased likelihood of distant recurrence and death, as compared with those with non-TNBC subtype. Regorafenib is a multi-receptor tyrosine kinase (RTK) inhibitor targeting oncogenesis and has been approved for metastatic colorectal cancer and advanced gastrointestinal stromal tumor. Recent studies suggest regorafenib acts as a SHP-1 ph...
متن کامل